Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
NCT02815007
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Interventions
DRUG:
Chidamide with EGFR-TKI
Sponsor
Yuankai Shi